Sensor augmented pump therapy(SAP) decreases glycemic variability(GV) and helps to prevent hypoglycemia. To evaluate the effect of SAP therapy on GV; percentage of time in range, time spent in hypo-hyperglycemia.
Mean pre-post SAP therapy HbA1c; GV and percentage of Levels 1 and 2 hypo-hyperglycemia and TIR were evaluated in type1diabetic patients followed up between Jan2016 and Nov2018.
Mean age and duration of DM was 12,25±0,62 and 5,75±4,68 years. Twenty of the patients were using standard insulin infusion pump therapy (IPT), 16 were on MDI, and 8 were newly diagnosed at the initiation of SAP therapy. Insulin doses (U/kg), bolus and basal insulin ratios were similar in pre-post SAP therapy after new diagnosis diabetics were excluded. No significant difference was found between the mean HbA1c of the IPT patients in the previous year and first year after SAP therapy on the 3rd,6th and 12th month.
Mean level 2 and 1 hypoglycemia and level 2 and 1 hyperglycemia rates were 0,55±0,52% and 2,13±1,26%; 9,32±10,33% and 20,14±6,27% consecutively. The rate of normoglycemia was 68,63±13,56% after SAP therapy.
In the 1-year follow-up period, mean GV index was measured at 3-month intervals. Although there was no statistically significant decrease in CV values, CV decreased from 36% to 33%. Secondary GV index SD decreased from 59.4 to 56 (p> 0.05)
As a result SAP therapy decreases GV while preventing hypoglycemia as shown by the decrease in SD and CV. With SAP therapy TIR was >65% and the time spent in hypoglycemia was very low.